Search

Your search keyword '"A. Schneeweiss"' showing total 885 results

Search Constraints

Start Over You searched for: Author "A. Schneeweiss" Remove constraint Author: "A. Schneeweiss" Topic female Remove constraint Topic: female
885 results on '"A. Schneeweiss"'

Search Results

1. Incorporating progesterone receptor expression into the PREDICT breast prognostic model

2. The BRCA2 c.68‐7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

3. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial

4. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.

5. Prediction of breast cancer risk based on profiling with common genetic variants.

6. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

7. Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.

8. Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

9. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.

10. Large-scale genotyping identifies 41 new loci associated with breast cancer risk

11. Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers

12. Genome-wide association studies identify four ER negative-specific breast cancer risk loci.

13. 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium

14. Genome-wide association analysis identifies three new breast cancer susceptibility loci

15. Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).

16. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial

17. A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

18. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial

19. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

20. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study

21. Stereotactic radiosurgery for brain metastases from pelvic gynecological malignancies: oncologic outcomes, validation of prognostic scores, and dosimetric evaluation

22. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

23. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

24. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics

25. Exercise restores brain insulin sensitivity in sedentary adults who are overweight and obese

26. Incorporating progesterone receptor expression into the PREDICT breast prognostic model

27. Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

28. Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis

29. Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice

30. Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial

31. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia

32. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment

33. Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients

34. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer

35. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials

36. Breast cancer risk factors and survival by tumor subtype

37. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy

38. Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

39. Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women

40. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study

41. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge

42. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

43. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry

44. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice

45. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees

46. Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity

47. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

48. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

49. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer

50. HER2-targeted therapy influences CTC status in metastatic breast cancer

Catalog

Books, media, physical & digital resources